Reassuring Q1 points to solid full year
03/05/21 -"Hikma has provided a reassuring Q1 21 business update – Injectables benefited from new launches while the momentum in Generics was driven by COVID-19-related products. While demand for such products ..."
Pages
48
Language
English
Published on
03/05/21
You may also be interested by these reports :
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...